Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PD-1 antibody-IL-15/IL-15Ra fusion protein IAP0971

A heterodimeric and bifunctional fusion protein composed of four chains: two heavy chains targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), one of which is fused to the cytokine interleukin-15 (IL-15) while the other one is fused to IL-15 receptor alpha (IL15Ralpha; IL15Ra) sushi domain, which fuses the IL-15/IL-15Ra sushi domain complex, and two anti-PD1 antibody light chains, with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of anti-PD-1 antibody-IL-15/IL-15Ra fusion protein IAP0971, the PD-1 targeting moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T cells and induces a T-cell-mediated immune response against tumor cells. The IL-15 moiety specifically binds to the IL-2/15Rbeta,gamma receptor and activates IL-15-mediated signaling. This stimulates the proliferation of natural killer (NK) cells, cytotoxic T lymphocytes (CTLs) and memory T cells locally in the in the tumor microenvironment (TME), and further induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2; CD273); it plays an important role in tumor evasion from host immunity. IL-15 regulates CD8+ T- and NK-cell development, activation and proliferation. IL-15Ra complexed with IL-15 domain improves stability. IAP0971 increases specific signaling of IL-15 in the TME due to the high expression of PD-1 in the TME, thereby preventing systematic non-specific IL-15-mediated signaling.
Synonym:anti-PD-1-IL-15 fusion molecule IAP0971
anti-PD1/IL-15-IL-15Ra Immunocytokine IAP0971
antibody-cytokine fusion protein IAP0971
PD1/IL15 immunocytokine IAP0971
Code name:IAP 0971
IAP-0971
IAP0971
Search NCI's Drug Dictionary